Stockholm, Sweden – Barnik Invest Group today announced an investment in Milmed Unico AB. Milmed is developing a novel therapeutic approach based on a unique yeast culture with demonstrated potential in treating various health conditions.
Milmed’s technology platform is built upon years of rigorous research, including pre-clinical studies conducted at Uppsala University and Sapienza University of Rome. This research has shown promising results in addressing neurodegenerative diseases, allergies, and inflammatory conditions.
“We are excited to support Milmed Unico AB and its innovative approach to treating a range of health challenges,” said Hamid Bakhshi, CEO of Barnik Invest Group. We believe that this investment and our long-term partnership with Milmed Unico AB will be instrumental in propelling the company forward and realizing the full potential of its innovative technology.”
Barnik Invest’s investment will support Milmed Unico AB in advancing its research and development efforts, with the goal of bringing this innovative therapy to patients in need.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: hamid.bakhshi@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for small Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully-owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development phase to commercialization, enabling them to achieve positive cash flows or successful exits and ultimately enhancing patient well-being and improving human health worldwide. For more information visit www.barnikinvest.com.
